SCHEMBL5448682

SCHEMBL5448682

Nc1ccc(Oc2cccc(Nc3nccc4c(-c5cccc(O)c5)cccc34)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 7/20 0.43
RAF1 P04049 6/20 0.43
ABCG2 Q9UNQ0 3/20 0.43
PIK3CD O00329 3/20 0.40
PIK3CA P42336 3/20 0.40
PIK3CG P48736 3/20 0.40
PIK3CB P42338 2/20 0.40
MTOR P42345 2/20 0.40
GLA P06280 1/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NLRP1 Q9C000 1/20 0.39
NOD2 Q9HC29 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5442716 0.85 ABCG2 (0.59) BRAFRAF1ABCG2HTTMEN1
SCHEMBL5448685 0.84 BRAF (0.49) BRAFRAF1ABCG2PIK3CDPIK3CA
SCHEMBL5450861 0.81 ABCG2 (0.53) BRAFRAF1ABCG2PIK3CDGLA
SCHEMBL5437465 0.78 BRAF (0.45) BRAFRAF1ABCG2PIK3CDPIK3CA
SCHEMBL5441105 0.77 IKBKB (0.47) BRAFRAF1ABCG2CSNK2A2CSNK2B
SCHEMBL5449527 0.76 BRAF (0.46) BRAFRAF1ABCG2PIK3CDPIK3CA
SCHEMBL5440503 0.75 ABCG2 (0.54) BRAFRAF1ABCG2HTTMAPT
SCHEMBL5450866 0.74 BRAF (0.50) BRAFHTTMEN1ALDH1A1KMT2A
SCHEMBL14574086 0.74 TSHR (0.47) ABCG2SMN1; SMN2EGFR
SCHEMBL5437478 0.73 ABCG2 (0.48) BRAFRAF1ABCG2PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007511570-A 2007-05-10 JP claimed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US claimed
EP-1689718-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY GLAXO GROUP LIMITED (GB) 2006-08-16 EP claimed
WO-2005049577-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 GLAXO GROUP LIMITED (GB) 2005-06-02 WO claimed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
EP-1689718-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
WO-2005049577-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 ALK, NPR3, CBR3 BRAF 1718/4885RAF1 1644/4885ABCG2 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.